Keywords
Last Name
Institution

IRINA AGOULNIK

TitleAdjunct Associate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Molecular & Cellular Biology
DivisionMolecular & Cellular Biology
AddressOne Baylor Plaza
MOLECULAR & CELLULAR BIOLOGY
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lopez SM, Agoulnik AI, Zhang M, Peterson LE, Suarez E, Gandarillas GA, Frolov A, Li R, Rajapakshe K, Coarfa C, Ittmann MM, Weigel NL, Agoulnik IU. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 Aug 1; 22(15):3937-49. PMID: 26968201; PMCID: PMC4970919 [Available on 08/01/17].
    2. Hu X, Myhr C, Huang Z, Xiao J, Barnaeva E, Ho BA, Agoulnik IU, Ferrer M, Marugan JJ, Southall N, Agoulnik AI. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry. 2016 Mar 29; 55(12):1772-83. PMID: 26866459.
      View in: PubMed
    3. Agoulnik IU, Agoulnik AI. Long-Lasting Consequences of Testosterone Exposure. Endocrinology. 2015 Oct; 156(10):3488-9. PMID: 26380936.
      View in: PubMed
    4. Hodgson MC, Deryugina EI, Suarez E, Lopez SM, Lin D, Xue H, Gorlov IP, Wang Y, Agoulnik IU. INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal. 2014; 12:61. PMID: 25248616; PMCID: PMC4181726.
    5. Hodgson MC, Vanostran G, Alghamdi S, Poppiti RJ, Agoulnik AI, Agoulnik IU. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One. 2013; 8(4):e60455. PMID: 23593223; PMCID: PMC3620158.
    6. Xiao J, Huang Z, Chen CZ, Agoulnik IU, Southall N, Hu X, Jones RE, Ferrer M, Zheng W, Agoulnik AI, Marugan JJ. Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nat Commun. 2013; 4:1953. PMID: 23764525.
      View in: PubMed
    7. Nakka M, Agoulnik IU, Weigel NL. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72. PMID: 23270728; PMCID: PMC3593820.
    8. Chen CZ, Southall N, Xiao J, Marugan JJ, Ferrer M, Hu X, Jones RE, Feng S, Agoulnik IU, Zheng W, Agoulnik AI. Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay. J Biomol Screen. 2013 Jul; 18(6):670-7. PMID: 23212924; PMCID: PMC4804196.
    9. Hodgson MC, Bowden WA, Agoulnik IU. Androgen receptor footprint on the way to prostate cancer progression. World J Urol. 2012 Jun; 30(3):279-85. PMID: 21927983; PMCID: PMC3360873.
    10. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget. 2011 Apr; 2(4):321-8. PMID: 21487159; PMCID: PMC3248162.
    11. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82. PMID: 21224358; PMCID: PMC3077543.
    12. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33. PMID: 20861284.
      View in: PubMed
    13. Li Z, Burzawa JK, Troung A, Feng S, Agoulnik IU, Tong X, Anderson ML, Kovanci E, Rajkovic A, Agoulnik AI. Relaxin signaling in uterine fibroids. Ann N Y Acad Sci. 2009 Apr; 1160:374-8. PMID: 19416222; PMCID: PMC2954601.
    14. Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80. PMID: 19416223; PMCID: PMC2945500.
    15. Agoulnik IU, Weigel NL. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74. PMID: 19463689; PMCID: PMC2687407.
    16. Agoulnik IU, Bingman WE, Nakka M, Li W, Wang Q, Liu XS, Brown M, Weigel NL. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32. PMID: 18787043; PMCID: PMC2582542.
    17. Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55. PMID: 18497048.
      View in: PubMed
    18. Feng S, Bogatcheva NV, Truong A, Korchin B, Bishop CE, Klonisch T, Agoulnik IU, Agoulnik AI. Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod. 2007 Oct; 77(4):671-80. PMID: 17615407.
      View in: PubMed
    19. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702. PMID: 17363522.
      View in: PubMed
    20. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 1; 66(21):10594-602. PMID: 17079484.
      View in: PubMed
    21. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 1; 99(2):362-72. PMID: 16619264.
      View in: PubMed
    22. Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 2006 Jul 1; 98(4):770-88. PMID: 16440331.
      View in: PubMed
    23. Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. The role of relaxin in endometrial cancer. Cancer Biol Ther. 2006 Jan; 5(1):71-7. PMID: 16322684.
      View in: PubMed
    24. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 1; 65(3):276-86. PMID: 16015593.
      View in: PubMed
    25. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 1; 64(4):362-72. PMID: 15754350.
      View in: PubMed
    26. Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 1; 65(17):7959-67. PMID: 16140968.
      View in: PubMed
    27. Agoulnik IU, Tong XW, Fischer DC, Körner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab. 2004 Dec; 89(12):6340-7. PMID: 15579801.
      View in: PubMed
    28. Agoulnik IU, Krause WC, Bingman WE, Rahman HT, Amrikachi M, Ayala GE, Weigel NL. Repressors of androgen and progesterone receptor action. J Biol Chem. 2003 Aug 15; 278(33):31136-48. PMID: 12771131.
      View in: PubMed
    29. James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705. PMID: 12456791.
      View in: PubMed
    30. Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, Harrison WR, Behringer RR, Overbeek PA. A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet. 2000 Dec; 26(4):490-4. PMID: 11101852.
      View in: PubMed
    31. Tong X, Engehausen DG, Freund CT, Agoulnik I, Oehler MK, Kim TE, Hasenburg A, Guo Z, Contant CF, Woo SL, Kieback DG. Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma. 1999 Feb; 18(1):93-7. PMID: 10211795.
      View in: PubMed
    32. Tong X, Shine DH, Agoulnik I, Freund CT, Hasenburg A, Aguilar-Cordova E, Woo SL, Kieback DG. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents. Anticancer Res. 1998 Sep-Oct; 18(5A):3421-6. PMID: 9858918.
      View in: PubMed
    33. Levy T, Agoulnik I, Atkinson EN, Tong XW, Gause HM, Hasenburg A, Runnebaum IB, Stickeler E, Möbus VJ, Kaplan AL, Kieback DG. Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Res. 1998 May-Jun; 18(3A):1345-9. PMID: 9673338.
      View in: PubMed
    34. Tong X, Engehausen DG, Freund CT, Agoulnik I, Guo Z, Oehler MK, Kim TE, Hasenburg A, Contant CF, Woo SL, Kieback DG. The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter. Anticancer Res. 1998 Mar-Apr; 18(2A):719-25. PMID: 9615711.
      View in: PubMed
    35. Tong XW, Engehausen DG, Kaufman RH, Agoulnik I, Contant C, Freund CT, Oehler MK, Kim TE, Hasenburg A, Woo SL, Kieback DG. Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy. Anticancer Res. 1998 Mar-Apr; 18(2A):713-8. PMID: 9615710.
      View in: PubMed
    36. Tong XW, Agoulnik I, Blankenburg K, Contant CF, Hasenburg A, Runnebaum LB, Stickeler E, Kaplan AL, Woo SL, Kieback DG. Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy. Anticancer Res. 1997 Mar-Apr; 17(2A):811-3. PMID: 9137412.
      View in: PubMed
    37. Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, Kaufman RH, Woo SL, Kieback DG. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996 May; 61(2):175-9. PMID: 8626129.
      View in: PubMed
    AGOULNIK's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _